MTAM Tech Corporation
MTAMTech strives to address and resolve key issues relating to the ineffective treatment of cancer patients through the personalization of treatment. Our technique is based on an extremely solid foundation, namely the US National Cancer Institute developed Hollow Fiber Assay (HFA). The combination of the HFA with our novel electrospun Microtube Array Membrane (MTAM) which consists of ultra-thin, one-to-one connected, sub-micron scale fiber and patient derived tumor cells (PDTC) allows us to present our product known as the MTAM-HFA technique for personalized medicinal use.
Compared to the current gold standard in the in vivo based anti-cancer drug screening-Patient Derived Xenograft (PDX), MTAM-HFA is capable of delivering in vivo based, highly translatable results within a clinically practical timeframe of 14 days, which translates to an 80% time reduction compared to the PDX model. Additionally, the cost associated with such a study accounts for only 20~40% of the conventional PDX model. Furthermore, the universal characteristic of the MTAM-HFA allows the usage of this technique for the screening of both solid and non-solid tumors. Lastly, this technique allows the screening of a large variety of drug classes including the recent area of focus, immunotherapy drugs.
In addition, new innovations have allowed us to use the same MTAM-HFA basis for application in the drug development pipeline, a high throughput active compound screening for pre-clinical development which delivers highly translatable in vivo data at a fraction of conventional cost, as well as the ability to assist drug developers to identify susceptible target patient segments for their leading drug candidate before clinical trials, thereby empowering them with a tool that can significantly reduce the risk associated with drug development. Currently, we are developing systems for the application in circulating tumor cells (CTC) capture that can potentially prevent metastasis and encapsulation cell therapy.
BRAXX Biotech
Esophageal cancer is the eighth most common cancer in the world. There are over 450,000 new cases each year. The standard treatment for esophageal cancer patients is multimodal, which includes surgery, chemotherapy and radiation therapy. Brachytherapy, as a simultaneous high-dose boost that delivers radiation internally within the body cavity, can bring better local control and survival rates. However, the radiation source, which is introduced into the esophagus through a nasogastric tube can result in uneven radiation exposure and severe side effects.
BRAXX’s innovative brachytherapy applicator is composed of multiple inflatable balloons for precise position control with high conformity to reduce side effects.
Asia accounts for more the 75% of new esophageal cancer patients every year and is our focus market. Our goal is to establish partnerships with leading companies in radiation therapy field and also enter markets in China, Japan and other potential regions.
Neurobit Technologies
Neurobit is a global healthcare company that is devoted to the development of easy-to-use, non-invasive, rapid screening cranial nerve health assessment tools that are based on innovative bio-design and big data analysis to enable earlier and more effective evaluation of human health of the cranial nerve.
We believe the development of medical devices for preventive medicine is an important trend in the healthcare field. Our rapid screening technique not only makes the clinical environment more convenient but also creates a healthier lifestyle. Neurobit was founded by a passionate and multidisciplinary team of medical and biomedical engineering professionals with experience in bio-design, intellectual property, regulation, data analysis, and marketing. Neurobit is currently collaborating with National Taiwan University Hospital and Tri-service General Hospital for clinical trials.
AllBio Life
AllBio's core focus is developing analysis platforms for antibody discovery and small molecule protein-drug interactions. Over the years, AllBio has established its expertise in the areas of gene sequencing, precision medicine, protein expression, and customized antibodies. With its two laboratories at the National Chiao Tong University and the National Chung Hsing University incubator center, AllBio services both the academic research and medical communities, and continues to develop new applications and technologies through its R&D division. When faced with the increasingly challenging research environment and the shortage of research resources, AllBio seeks to leverage innovative technologies from both basic and clinical research to help advance Taiwan's medical and health industries to the age of big data and digital health.
MEDIOT
MEDIOT's goal is to build an internet based video communication system to increase the accessibility of healthcare services for the people. Harvard economics professor Michael Porter posits that a well-established healthcare system requires an integrated practice unit (IPU) that combines all medical professionals in the way to provide highly efficient care for specific patients.
The formation of an IPU requires not only a diversity of medical divisions but also a patient-oriented integrative process. In order to achieve this goal, our development allows patients to connect to specific types of health providers in any place without the restrictions of open hours of physical clinical units. In other words, the "air" matchmaking mobile system increases accessibility to health providers by putting a personal medical team in the patient's pocket.
Our product, Medobrick, is a personal online healthcare system allowing users to receive real-time and online-to-offline (o2o) health information. Medobrick is a modular product which comprise a major video communication module and several other prognosis modules for healthcare usage.
Lin BioScience
Lin BioScience is a drug development company. We license-in first-in-class technologies and drugs from the top research institutes, such as Columbia University, Memorial Sloan Kettering Cancer Center and Sydney University. Lin BioScience continues research and development on the technologies and drugs to fulfill a variety of unmet medical needs.
LBS-008: First-in-Class Oral Therapy for Treatment of Macular Degeneration
LBS-008 is a first-in-class oral therapy targeting Dry Age-Related Macular Degeneration (AMD) and Stargardt Disease, which are untreatable conditions that cause vision loss in adults and children, respectively. LBS-008 is the most advanced and the first graduate candidate from the US National Institutes for Health’s (NIH) highly selective Blueprint Program for Neuroscience Research. The program leverages the resources of 15 NIH centers and $10M USD in funding to cover the development cost of LBS-008 through completion of Phase 1 clinical trials. LBS-008 has obtained US FDA Orphan Drug Designation in 2017 and is expected to enter first-in-human Phase 1 clinical trials in 2018.
LBS-007: Natural Small Molecular Inhibitor for Treatment of Cancers
LBS-007 is a novel targeted therapy for the treatment of a broad array of cancers. It has demonstrated activity against leukemia and solid tumors, especially in chemotherapy-resistant cell lines and other cancer cell lines.
LBS-002: First-in-Class Anti-Tubulin for the Treatment of Primary and Metastatic Brain Tumors
LBS-002 is a first-in-class anti-tubulin therapy targeting primary glioblastomas and metastatic brain tumors resulting from breast and lung cancers. LBS-002 displays the same drug-like properties as CNS-active drugs and is the first anti-tubulin agent to be able to cross the blood-brain barrier (BBB). Pre-clinical data shows that LBS-002 is highly efficacious in aggressive, chemo-resistant brain cancers (including EGFR-mutant glioblastomas in vivo) and exhibits a better therapeutic window than clinically used tubulin inhibitors.
Jowin Biopharma
Jowin Biopharma is structured as an R&D engine to develop new drugs in preclinical and clinical stages, then transfer the technology to other parties for later stage development. Currently we are working on targeted therapies for lung cancer using PDC technology, where a targeting peptide is used as a carrier. Other research areas include developing immuno-modulation drugs for allergic indications such atopic dermatitis.
Two new drugs are currently under development. One is for targeted therapy of non-small cell lung cancer (NSCLC) and another is on atopic dermatitis (AD). For NSCLC drugs, we consider our new developing drug as the second generation of Alimta® which has No.1 market share among all NSCLC drugs. As the standard care of NSCLC treatment in first, second and third line treatment, its sale volume should remain high for the foreseeable future. Current revenue for Alimta® is US$25B. The new drug under development will be the targeting version of Alimta®, and its main competition will be the original version of Alimta®.
For AD drugs, our new drug under development has proved its efficacy of immune-modulation on the cell lines, which showed its capability to modulate inflammation-related cytokine levels. The effect is comparable to that of Dupixent®, the most promising blockbuster drug in 5 years. The AD market was US$7.2B in 2017 and will grow to US$24 B in 2027. Most competitors are antibodies under development at different clinical stages.
uMeal Food Co
uMEAL delivers low-GI cooked meals to diabetics’ in Taipei City and New Taipei City. We also deliver high protein, low-GI meals to those who work out in order to build and maintain shapely bodies. Our menus are designed by a Columbia dietitian and our professional head chef. Our meals strike an expert balance between taste and health.
Our target customers are diabetics’ who want to regain the joy of food, as well as people who care about health and food safety, people looking to lose weight but do not want to diet, people who love fitness and exercise and need higher levels of protein.
We are forming cross-industry alliances with blood glucose machine manufacturers, gyms, etc., and have an active presence on social media and our website is optimized for search engines.
According to 《Global Diabetes Report》, World Health Organization (WHO) 2016, there are 422 million diabetics in the world. 2.27 million of those are in Taiwan. According to the Transparency Market Research and Institute of Biotechnology Industry Research (2016), Taiwan
Economic Research Institute, the global diabetes food market will grow to 11.1 billion U.S. dollars in 2020, while the market in Taiwan will grow to 0.23 billion U.S. dollars in 2020.
Instant NanoBiosensors
Instant NanoBiosensors Corporation (INB) is a biosensing platform developer.
Our rapid POCT (Point-of-Care Testing) system, based on the first in the world unique and patented fiber optic particle plasmon resonance (FO-PPR) technology, was developed by Dr. Lai-Kwan Chau, Professor of Chemistry and Biochemistry at the National Chung Cheng University. Currently, INB
continues to grow rapidly, as we find exciting new markets and innovative uses for our groundbreaking, proprietary technology.
When it comes to waiting for diagnostic results, speed matters in POCT. Rapid and precise diagnostics make a crucial difference by saving time, money, scarce resources and lives. INB's POCT platform, is the fastest and most precise detector. The ability to produce accurate test results in any location, without a full lab or special training and faster than the most expeditious versions of current testing trends is revolutionary. These innovative benefits carry immense weight, not only for state-of-the-art diagnostic services, but also for the care of every single person in your family that does not need a full laboratory or fully-trained professionals.
Ultrondata Driven
Insufficient nursing capacity is the most critical problem for long-term care. As a digital solution provider, Ultrondata focuses on helping to relieve the pressure of nursing staff while increasing the level of personalized care. Our sevice, iParents, includes a digital assistant for elderly to self-care and digital solutions for nursing homes. With iParents, long-term care can be easier and more efficient.
Other products and systems under development include our uCare Hospital Information system, uNurse Nurse Call System, uBed Bedside System, Chatbot Development as well as Companion Robot Development. At a B2B level, we work directly with hospitals and nursing staff, and B2C with the iParent app and chatbot service.
MicroMED Co
MicroMED owns a novel and powerful MEMS (MicroElectroMechanical System) micropump platform technology. Our proprietary MEMS platform technology provides a flexible customization service for a wide variety of drug delivery applications: from implantable to wearable devices, animal to human, small (m) to large (cm) device footprints, slow (nL/Hr) to fast (mL/sec) delivery rates, small (pg) to large dose (g), small molecule to biologics drug compatibility, and 510k to 505b2 regulatory paths.
Our mission is to create an innovative drug delivery micropump platform to accelerate the process of drug discovery and development.
MicroMED’s revolutionary, ground-breaking drug delivery platform using micro/nano technology with simple & safe formulation tactics targeting the current system-level bottlenecks can easily save 3-5 years of time and up to half to a billion dollars for a single drug program from initial compound screening to final market launch.
Hygeia Touch
HygeiaTouch is developing an in vitro diagnostic medical device (IVD) that can be provided to women for self-testing for the human papilloma viruses (HPV). Design and development will be carried out in accordance with the relevant specifications for product safety and operability.
At present, there are no medical devices clearly labeled "Self-sampling cervical and vaginal cells" on the market. Clinical validation of a sufficient number of subjects is required for self-sampling. Therefore, most of the devices for vaginal cell sampling at home and abroad have not been clinically validated.
Since there is no product labeling “self” or “home-use” in Taiwan, our product will become the exclusive market for “female HPV self-testing” and the market share will be 100%. According to the latest announcement issued by the National Health Administration, there were approximately 2.355 million females who underwent Pap smear examinations in Taiwan in 2016. There is also literature which shows that about 87% of women are willing to use a self-sampling stick for HPV testing and also willing recommend it to friends, and 65.2% of women believe that the self-testingapproach does solve women's unwillingness to do cervical cancer screening
Flat Medical
Founded in 2015, and comprised of founders from mechanical engineering, biomedical engineering and clinical medicine, Flat Medical focuses on safety issues for clinical procedures. Through deep research, discussion with clinical and development professionals, we aim to keep delivering high value, affordable medical technologies to everyone.
Our first product is a safeguard for epidural analgesia, which is indicated for painless labor, chronic pain management and surgical anesthesia. Under current practices, anesthesiologists rely on their manual sense to locate the needle into a small space of 1-3 mm, which reveals a high risk of accidental puncture into spinal cord, leading to paralysis. We provide a visual, fool-proof mechanism to eliminate this risk. The product is in design freeze and finished pilot production, and will get approval from FDA and CE by the end of this year. A first-human trial for marketing will be conducted in Q4, 2018. We are also planning a trial in renowned medical center in the U.S. next year.
Space Apes
Space Apes was founded in May of 2017. It consist of 5 members with diverse backgrounds including design, engineering, medical and chemical industries. We share a passion for resolving the global water crisis with our unique specialities, creating a better tomorrow for all human beings.
Space Apes aims to solve the issue of water scarcity with our patented atmospheric water generator, AQR. This non-electric device can reduce death rates related to contaminated water and enhance living quality by shortening the time required to gather drinkable water.
Our AQR adsorbs water vapor from the air at night using a specialized adsorbent. During the day, sunlight is concentrated through lenses on top of the AQR triggering the release of the water. The next step is cleaning, which will be done by a cleansing system in the lower part of the AQR. The whole process requires no electric power, which is totally eco-friendly.
AQR has received both iF public value and green product awards at 2016 from Germany.
Ethersection Labs
Ethersection Labs is a blockchain company developing solutions for problems in IoT and digital health. The product featured in this accelerator is “Ncent”, a mobile blockchain-based app that is a scalable solution to the adherence problem for wellness and addiction-related goals. Ncent works with the sensors you already carry around with you in your phone, and is also compatible with wearables and smart pills.
With Ncent, users set a goal, stake some cash in the form of cryptocurrency, and then Ncent breaks the goal into milestones. When a user completes their milestones, they earn back portions of their stake along with a little extra “Ncentive”. If they fail, their loss is used to incentivize other users and to fund the platform. Since Ncent uses activity recognition algorithms and blockchain-based smart contracts, it eliminates all overhead for the user and the platform in verifying the truthiness of the user’s progress, and facilitating payments.